- Home
- OPTN
OPTN
OptiNose Inc.
as 07-26-2024 4:00pm EST
OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms, a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | YARDLEY |
| Market Cap: | 123.2M | IPO Year: | 2017 |
| Target Price: | $3.67 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.27 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.80 - $2.10 | Next Earning Date: | 08-08-2024 |
| Revenue: | $74,022,000 | Revenue Growth: | 0.90% |
| Revenue Growth (this year): | 32.73% | Revenue Growth (next year): | 46.83% |
Stock Insider Trading Activity of OptiNose Inc. (OPTN)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Mahmoud Ramy A | OPTN | Chief Executive Officer | Jul 17 '24 | Sell | $1.14 | 111,426 | $127,025.64 | 1,206,978 | SEC Form 4 |
| Marino Michael F III | OPTN | Chief Legal Officer & Corp Sec | Jul 17 '24 | Sell | $1.14 | 49,408 | $56,325.12 | 550,464 | SEC Form 4 |
| Krick Anthony J | OPTN | Chief Accounting Officer | Jun 18 '24 | Sell | $1.19 | 624 | $742.56 | 143,364 | SEC Form 4 |
| Marino Michael F III | OPTN | Chief Legal Officer & Corp Sec | Jun 18 '24 | Sell | $1.19 | 2,946 | $3,505.74 | 599,872 | SEC Form 4 |
| Marino Michael F III | OPTN | Chief Legal Officer & Corp Sec | Jun 15 '24 | Sell | $1.19 | 3,267 | $3,887.73 | 602,818 | SEC Form 4 |
| Mahmoud Ramy A | OPTN | Chief Executive Officer | Jun 15 '24 | Sell | $1.19 | 18,987 | $22,594.53 | 1,318,404 | SEC Form 4 |
| Krick Anthony J | OPTN | Chief Accounting Officer | Mar 18 '24 | Sell | $1.88 | 2,345 | $4,408.60 | 143,988 | SEC Form 4 |
| Marino Michael F III | OPTN | Chief Legal Officer & Corp Sec | Mar 15 '24 | Sell | $1.88 | 15,059 | $28,310.92 | 602,268 | SEC Form 4 |
| Mahmoud Ramy A | OPTN | Chief Executive Officer | Mar 15 '24 | Sell | $1.88 | 19,198 | $36,092.24 | 1,331,278 | SEC Form 4 |
| Mahmoud Ramy A | OPTN | Chief Executive Officer | Jan 31 '24 | Sell | $1.31 | 52,875 | $69,266.25 | 548,387 | SEC Form 4 |
| Mahmoud Ramy A | OPTN | Chief Executive Officer | Dec 15 '23 | Sell | $1.15 | 11,114 | $12,781.10 | 509,728 | SEC Form 4 |
| Marino Michael F III | OPTN | Chief Legal Officer & Corp Sec | Dec 15 '23 | Sell | $1.15 | 5,005 | $5,755.75 | 333,511 | SEC Form 4 |
Latest OptiNose Inc. News
OPTN Breaking Stock News: Dive into OPTN Ticker-Specific Updates for Smart Investing
Zacks
10 days ago
Profound Medical (PROF) Surges 6.0%: Is This an Indication of Further Gains?
GlobeNewswire
a month ago
Expanded Access to XHANCE with Addition to National Commercial Formularies
Simply Wall St.
2 months ago
When Will OptiNose, Inc. (NASDAQ:OPTN) Breakeven?
GlobeNewswire
2 months ago
Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
Thomson Reuters StreetEvents
2 months ago
Q1 2024 OptiNose Inc Earnings Call
GuruFocus.com
2 months ago
OptiNose Inc (OPTN) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and Financial ...
Zacks
2 months ago
OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates
Associated Press Finance
2 months ago
OptiNose: Q1 Earnings Snapshot
Compare OPTN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OPTN OptiNose Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.